News
NUWE
2.505
-39.64%
-1.645
Nasdaq Down 2%; Alphabet Posts Upbeat Earnings
U.S. Stocks traded lower on Wednesday, with the Dow Jones down around 400 points. The NASDAQ fell 2.08% and the S&P 500 traded down 1.47%. Alphabet Inc posted better-than-expected earnings and sales results for its second quarter. Utilities shares jumped by 0.3% on Wednesday. Asian markets closed lower while European shares were mostly lower.
Benzinga · 3h ago
Nuwellis to sell ~0.47M shares at $4.24 in registered direct offering
Healthcare Nuwellis to sell ~0.47M shares at $4.24 in registered direct offering. The gross proceeds from the offering are expected to be $2M. The company intends to use the net proceeds for working capital and for general corporate purposes.
Seeking Alpha · 4h ago
Nuwellis Announces Pricing Of $2M Offering Of 469,340 Shares Of Common Stock At A Price Of $4.24 Per Share, Priced At-The-Market Under Nasdaq Rules
Benzinga · 6h ago
NUWELLIS ANNOUNCES PRICING OF $2.0 MILLION OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES
Reuters · 6h ago
Press Release: Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024
Dow Jones · 22h ago
Weekly Report: what happened at NUWE last week (0715-0719)?
Weekly Report · 2d ago
Nuwellis reports first commercial sale of Quelimmune therapy to Cincinnati Children’s
Nuwellis reports first commercial sale of Quelimmune therapy to Cincinnati Children’s. Early clinical data suggest a 77% survival rate for patients treated with this new therapy. Nuwellis (NUWE) down -5.02% to $4.35.
Seeking Alpha · 07/17 13:42
Nuwellis Achieves First QUELIMMUNE™ Sale, Cautions Investors
TipRanks · 07/17 13:27
Nuwellis Marks First Commercial Sale Of QUELIMMUNE Therapy To Cincinnati Children's For Pediatric Patients Suffering From An Uncontrolled Inflammatory Response Triggered By Their Immune Systems
Nuwellis announces first commercial sale of QUELIMMUNE to Cincinnati Children's. The therapy is a novel therapy developed by SeaStar Medical Holding Corporation for pediatric patients suffering from an uncontrolled inflammatory response. Early clinical data suggest a 77% survival rate for patients treated with this new therapy.
Benzinga · 07/17 13:08
NUWELLIS MARKS FIRST COMMERCIAL SALE OF QUELIMMUNE™ THERAPY TO CINCINNATI CHILDREN’S
Reuters · 07/17 13:00
Weekly Report: what happened at NUWE last week (0708-0712)?
Weekly Report · 07/15 10:04
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Crown LNG stock is rocketing almost 154% after completing a business combination. Crown LNG is one of 10 top pre-market stock movers to watch on Friday morning. The biggest pre- market stocks to watch are mergers, clinical trial data, public offerings and more.
Investorplace · 07/12 11:41
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Mainz Biomed shares jumped 16% in today's pre-market trading. Pineapple Energy Inc. Shares rose 85% to $2.22 in pre- market trading. The company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test.
Benzinga · 07/09 09:33
Nuwellis Granted European Patent EP3873343 For "Neonatal And Pediatric Blood Filtration System"
Benzinga · 07/08 16:19
Weekly Report: what happened at NUWE last week (0701-0705)?
Weekly Report · 07/08 10:04
Nuwellis Ends Stock Sale Agreement with Ladenburg Thalmann
TipRanks · 07/03 20:59
NUWELLIS - ON JULY 1, DELIVERED NOTICE TO LADENBURG THALMANN & CO. TO TERMINATE ITS AT MARKET OFFERING AGREEMENT, DATED MARCH 3, 2023
Reuters · 07/03 20:33
Nuwellis files for $25M mixed securities shelf
Seeking Alpha · 07/01 21:15
BRIEF-Nuwellis Files For Mixed Shelf Of Up To $25 Million - SEC Filing
Reuters · 07/01 21:07
Weekly Report: what happened at NUWE last week (0624-0628)?
Weekly Report · 07/01 10:05
More
Webull provides a variety of real-time NUWE stock news. You can receive the latest news about Nuwellis Inc through multiple platforms. This information may help you make smarter investment decisions.
About NUWE
Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.